Reply to: 'The use of β-blockers after myocardial infarction: no doubts remain'.

This reply addresses the ongoing debate regarding the universal applicability of beta-blockers post-myocardial infarction (MI), particularly in the era of early revascularization and modern medical therapy. The author emphasizes that while beta-blockers remain crucial for MI patients with heart failure or reduced ejection fraction, their routine, long-term use in all MI patients, especially those with preserved ejection fraction and without ongoing ischemia, lacks robust evidence from contemporary randomized controlled trials. The clinical implication is a call for more nuanced, evidence-based prescribing practices, moving away from a "one-size-fits-all" approach to beta-blocker therapy post-MI, and encouraging re-evaluation of their benefit in specific patient subgroups.